While the number of people suffering from brain disorders continues to increase in the modern aging society, it is still a challenge to develop effective treatments for many of these diseases. For example, the risk of Alzheimer' s disease (AD), an age-dependent disorder, doubles every five years after the age of 65. However, there is still no medication to treat AD. While pharmaceutical means offers the highest patient compliance, it is difficult to discover an effective drug for brain disorders because of the existence of the brain-blood barrier (BBB) within the brain capillary endothelia [1]. BBB, a tight junction that exists between the blood vessel and extracellular space of the brain, allows passage of only a fraction of small-molecule drugs. In addition to this physical limitation, the pharmacological approach suffers from drug resistance, sideeffects, tolerance, and dependence, which further complicates the